Search
Powered By HealthLine
Special Offers
TV Specials
 Learn about an Effective Alzheimer's Medication
 Bipolar Education Health Center
 Osteoarthritis of the Knee Solution Center
 Heartburn Education Center
 Breast Cancer Health Center
 Crohn's Disease Health Center
 Schizophrenia Education Center
Top Features
 Depression
 Schizophrenia
 Breast Cancer
 Bipolar
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

FDA OKs 1st Over-the-Counter Weight-Loss Drug


Related Encyclopedia
 border=
Abdominoplasty
Acidophilus
Ankle Sprains
Antioxidants
More...

Related Healthscout Videos
 border=
Hungry Heart
Power Out Fat
Soy - Many Forms, Many Benefits
Soy - Health Benefits Explained
More...

Related Drug Information
 border=
Klor-Con
Klor-Con ER
More...

Related News Articles
 border=
FDA Warns Epilepsy Drugs May Raise Suicide Risk
Quit-Smoking Drug May Raise Suicide Risk
Folic Acid May Help Prevent Premature Birth
Atkins-Like Diet Cuts Epileptic Seizures
More...


Page:  << Prev | 1 | 2 | 3 | Next >>

"This drug is only going to be effective if it's used along with a weight-loss program," Ganley said. "That means a reduced-fat diet, decreased calories and an exercise program."

"If someone uses the drug without a weight-loss program, it's not going to be very effective," he added.

A higher dose of orlistat (120 milligram capsules) has been marketed as the prescription drug Xenical in the United States since 1999.

Text Continues Below



While the company claims Xenical's safety has been demonstrated by nine years of worldwide use in 146 countries, the consumer-advocacy group Public Citizen last year petitioned the FDA to remove Xenical from the U.S. market.

Public Citizen contended that the higher-dose drug might increase the risk of aberrant crypt foci, which are widely believed to be precursors to colon cancer.

Late Wednesday, the advocacy group issued a statement criticizing the FDA's approval of the over-the-counter version of the drug.

"At a time when colon cancer is a leading cause of death and disease in the United States, the Food and Drug Administration's decision to approve, for over-the-counter use, a diet drug that clearly causes precancerous lesions of the colon is the height of recklessness and shows a profound lack of concern for the public's health," Dr. Sidney M. Wolfe, director of Public Citizen's Health Research Group, said in the statement.

One obesity expert isn't sure the new OTC drug will be effective for most people.

"The drug is probably safe," said Dr. Raj Padwal, an assistant professor of general internal medicine at the University of Alberta. "However, I'm not sure the half-strength dosage will have much effect."

Full-strength dosage reduces weight by less than 3 kilograms (6.6 pounds), on average, Padwal said.

"People may only lose 1 to 2 kilograms (2.2 to 4.4 pounds) on this half-strength dose. Whether that is worthwhile is questionable. The occasional patient may benefit, but many patients may not. For those patients who need extra incentive to adhere to a low-fat diet, the drug may help," Padwal said.

Page:  << Prev | 1 | 2 | 3 | Next >>

Copyright © 2007 ScoutNews, LLC. All rights reserved.
Last updated 2/8/2007

Related Links
 border=
From Healthscout's partner site on diet & exercise, MyDietExercise.com
QUIZ: What's your ideal body weight?
QUIZ: Check your body mass index (BMI) online!
QUIZ: Rate your carbohydrate intake





New Features

New ADHD Site!

SOURCES: Feb. 7, 2007, U.S. Food and Drug Administration teleconference with Charles J. Ganley, M.D., director, Division of Over-The-Counter Drug Products, Washington, D.C.; Raj Padwal, M.D., assistant professor, general internal medicine, University of Alberta, Edmonton, Canada; David L. Katz, M.D., associate professor, public health, and director, Prevention Research Center, Yale University School of Medicine, New Haven, Conn.


About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service   Site Map